People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Hoth Therapeutics, Inc. | — | Pharmaceuticals | Series A | $33.7M | $100.5M | 2023 |
| Silo Pharma, Inc. | — | Pharmaceuticals | Series A | $11.2M | $11.6M | 2024 |
Jeff Pavell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeff Pavell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Wayne Linsley | 2 | 3 |
| Anthony Hayes | 1 | 7 |
| Vadim Mats | 1 | 3 |
| Leonard Schiller | 1 | 3 |
| Eric Weisblum | 1 | 2 |
| Robb Knie | 1 | 2 |
| David Briones | 1 | 2 |
| Kenneth Rice | 1 | 2 |
| Graig Springer | 1 | 1 |
| Stefanie Johns | 1 | 1 |
| David B. Sarnoff | 1 | 1 |
| Kevin Munoz | 1 | 1 |
| Daniel Ryweck | 1 | 1 |
| Wayne D. Linsley | 1 | 1 |
| Kevin D. Munoz | 1 | 1 |
| Joel Stone | 1 | 1 |
| Van Parker | 1 | 1 |
| David Sarnoff | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.